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Transient visual disturbances constitute the most commonly reported neurological side effect during and immediately
after sclerotherapy. A few studies, based on clinical and diffusion-weighted MRI assessments, have suggested that these
transient neurological symptoms correspond to migraine with aura. Recently, it has been reported that brain magnetic
resonance imaging can reveal transient T2*-weighted abnormalities during the acute phase of migraine with aura. We
reported a 36-year-old man who presented with transient neurological symptoms and concomitant T2*-weighted
abnormalities on brain magnetic resonance imaging immediately after liquid sclerotherapy. We hypothesize that
the reversible nature of the patient’s T2*-weighted abnormalities may indicate a relationship with the post-sclerotherapy
migraine with aura attack.
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Transient visual disturbances constitute the most com-
monly reported neurological side effect during and im-
mediately after sclerotherapy, with an incidence of 1.4%s
[1]. Furthermore, foam sclerotherapy appears to be asso-
ciated with a higher incidence of transient visual dis-
turbances than liquid sclerotherapy [2]. Research has
suggested that these transient neurological symptoms
(which are more frequent in patients with patent foramen
ovale (PFO) and/or a history of migraine) correspond to
migraine with aura (MA) [3-5].
More recently, it has been reported that brain mag-
netic resonance imaging (MRI) can reveal transient
T2*-weighted abnormalities during the acute phase of
MA [6-8].
Here, we report on a patient who presented with tran-
sient neurological symptoms and concomitant T2*-
weighted abnormalities on MRI immediately after liquid
sclerotherapy. We hypothesize that the reversible nature
of the patient’s T2*-weighted abnormalities may indicate
a relationship with the post-sclerotherapy MA attack.* Correspondence: bugnicourt.jean-marc@chu-amiens.fr
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A 36-year-old man presented with symptomatic but
moderate varicosity of the left small saphenous vein.
The patient had no vascular risk factors, no history of
venous diseases, no family history of migraine and no
reported migraine comorbidities. He reported a few epi-
sodes of headache, the description of which was com-
patible with migraine without aura. In February 2014,
he underwent liquid sclerotherapy (carried out in ac-
cordance with the European consensus statement) [9].
After contraindications to treatment were ruled out and
the patient had given his written, informed consent, the
first sclerotherapy session (with a total of 2 ml of 0.25%
lauromacrogol solution) was not followed by any com-
plications. Two weeks later, the patient received a sec-
ond injection of 4 ml of 0.25% lauromacrogol solution.
Immediately following the injection, the patient reported
flickering lights in his right eye and several minutes of
photopsiae, followed by right hemianopsia. These symp-
toms disappeared after two hours. Two weeks later, the
patient underwent a third sclerotherapy (with 4 ml of
0.25% lauromacrogol solution). Immediately following in-
jection of the liquid, the patient again reported flickering
lights in his right eye, followed by right hemianopsia and
(two hours later) the progressive onset of aphasia and
psychomotor slowing. Comprehension was not affected.
An evaluation by a neurologist revealed headache, rightan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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progressing disturbance of consciousness. The National
Institutes of Health Stroke Scale (NIHSS) score was 4
out of 42 [10]. Brain MRI (performed three hours after
symptom onset) was normal. However, gradient-echo
T2*-weighted images revealed several hypointense areas
in both hemispheres of the brain (though predomin-
antly in the left hemisphere) (Figure 1A). The patient’s
movement prevented us from interpreting the results
of magnetic resonance angiography of the Circle of
Willis. Since the acute symptoms persisted, acute en-
cephalopathy was suspected. Although the results of a
cerebrospinal fluid analysis were normal, treatment with
acyclovir was initiated. The chest radiography was un-
remarkable. The electrocardiogram, carotid ultrasonog-
raphy, transcranial Doppler ultrasound and transthoracic
echocardiography results were normal. The laboratory
test results (including thyroid function, arterial blood gas
measurement, and syphilis screening tests) were also nor-
mal. The coagulation work-up did not show any factor V
Leiden or prothrombin gene G20210A mutations, and
protein C, protein S, antithrombin III, factor VIII and
homocysteine levels were normal. Antibody screening
was negative. Transoesophageal echocardiography re-
vealed a PFO with an associated atrial septal aneurysm. A
color flow duplex scan revealed a moderate right-to-
left shunt but only during provocation tests. The car-
diac valves were normal, and there was no evidence of
aortic atheroma or pulmonary arterial hypertension.
The colour duplex ultrasonography results for the lowerFigure 1 A gradient-echo T2*-weighted magnetic resonance image sh
especially in the left hemisphere (A) and a normal gradient-echo T2*-
migraine attack (B).limbs were normal. After 48 h, the symptoms (including
the headache) resolved spontaneously and the patient
was diagnosed with probable migraine with aura (on the
basis of this first episode of migraine with prolonged
aura). Brain MRI was repeated five days after symptom
onset and the T2* images were normal (Figure 1B). The
patient was discharged six days after admission, with a
favourable outcome (NIHSS score: 0). Following hospi-
talisation, the patient suffered from to other episodes of
migraine with aura lasting for less than 1 hour.
Conclusions
In migraine with aura, visual disturbances may comprise
additional features (such as flickering lights and spots),
or the loss of features (such as hemianopia and loss of
vision) and may be associated with sensory disturbance
and speech impairment (depending on the extent of
cortical spreading depression (CSD) [1,11]. These
complications appear to be more frequent after foam
sclerotherapy than after liquid sclerotherapy [2]. Al-
though the degree to which the injected volume of scler-
otic agent contributes to the development of neurological
side effects is subject to debate, it appears reasonable to
decrease the volume when (i) neurological symptoms oc-
curs after sclerotherapy and (ii) another sclerotherapy
session is required [11]. Recent clinical and brain MRI
studies have shown that these transient neurological
symptoms (which are more frequent in patients with
PFO) correspond to MA rather than to transient
ischemic events [5,12].owing hypointense signals in both hemispheres of the brain but
weighted magnetic resonance image acquired five days after the
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graine sufferers [13]. It is clinically defined by at least
two recurrent episodes of fully reversible symptoms (the
most frequent of which are visual disturbances, sensory
disturbances and speech and/or language impairment).
The aura symptom spreads gradually over a period of
5 minutes and (for each individual aura) lasts between
5 and 60 minutes (although this upper limit was set
arbitrarily). Indeed, it has been reported that aura lasts
for more than one hour in up to 37% of patients [14].
This epidemiological reality has been recently taken
into consideration in the third edition of the Inter-
national Classification of Headache Disorders, in which
aura lasting more than an hour but less than a week (in
the absence of radiologically confirmed brain ischemia)
was defined as “probable migraine with aura (prolonged
aura)” [15]. These atypical clinical presentations always
warrant a thorough work-up, since cerebrovascular dis-
ease must be always considered [16]. As such, brain
MRI is usually required to carefully screen for the under-
lying cause during the acute phase. Recently, transient
T2*-weighted imaging abnormalities on brain MRI
have been reported during the acute phase of MA
[6-8]. The occurrence of these transient T2*-weighted
imaging abnormalities after sclerotherapy lends sup-
port to the hypothesis whereby endothelin release and
microembolization trigger CSD [17]. The two most likely
explanations for these T2* findings relate to (i) increased
oxygen consumption and a subsequent increase in the
intravenous deoxyhaemoglobin concentration [18] and
(ii) venous dilatation following the release of vaso-
active factors (such as endothelin). In murine models,
systemic levels of endothelin-1 (ET-1, one of the most
potent vasoconstrictors and a CSD inducer) are sig-
nificantly elevated one and five minutes after the initi-
ation of foam sclerothapy [19]. Furthermore, Lemos
et al.'s study of a population of Portuguese patients
revealed a possible role for the endothelin receptor type A
in migraine without aura [20]. Nevertheless, the preva-
lence and significance of these phenomena merit further
investigation.
In conclusion, the present observation suggests that
the transient nature of the T2*-weighted imaging abnor-
malities is associated with a CSD caused by migraine
aura after sclerotherapy.
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